QUILT-3.002: ALT-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
|3||Not yet recruiting||
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
† Study has passed its completion date and status has not been verified in more than two years.